Reasons for Growth Investors to Consider Buying Neurocrine (NBIX) at This Time
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Should l Buy NBIX?
Source: NASDAQ.COM
Growth Investing Overview: Growth investors seek stocks with above-average financial growth, but these stocks come with higher risks and volatility. Identifying strong growth stocks can be challenging.
Neurocrine Biosciences Recommendation: Neurocrine Biosciences (NBIX) is highlighted as a strong growth stock due to its favorable Growth Score and top Zacks Rank, indicating potential for solid returns.
Key Growth Metrics: Neurocrine's projected EPS growth of 99.6% this year and year-over-year cash flow growth of 35.4% significantly surpass industry averages, making it an attractive option for growth investors.
Earnings Estimate Revisions: The upward trend in earnings estimate revisions for Neurocrine, with a 15.4% increase in the current-year estimates, further supports its strong growth potential and Zacks Rank #1 status.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBIX
Wall Street analysts forecast NBIX stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 129.540
Low
143.00
Averages
179.68
High
203.00
Current: 129.540
Low
143.00
Averages
179.68
High
203.00
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Equifax Named 'Stock to Study' for May 2026 by BetterInvesting
- Investor Interest: Equifax's recent report has sparked investor curiosity regarding whether its stock is fairly valued, leading BetterInvesting's Editorial Advisory Committee to designate it as a 'Stock to Study' for May 2026, aimed at providing information and education for investors.
- Transparency in Fundamentals: Investors can access Equifax's sales, earnings, pre-tax profit, and return on equity through a link provided by the National Association of Investors, enhancing transparency and aiding investors in making informed decisions.
- Independent Review Committee: The Editorial Advisory Committee of BetterInvesting comprises several CFA charterholders, whose independent evaluations provide deeper analytical insights, thereby increasing the research value of Equifax's stock.
- Educational Mission: Since its establishment in 1951, BetterInvesting has focused on investment education, empowering over 5 million individuals to improve their financial futures, emphasizing the importance of independent analysis before making investment decisions.
See More
Equifax Named 'Stock to Study' by BetterInvesting
- Investment Research Recommendation: Equifax has been named 'Stock to Study' for the May 2026 issue of BetterInvesting, indicating a rising interest among investors that may attract further research and investment interest.
- Transparency in Fundamentals: Investors can access key financial metrics such as sales, earnings, pre-tax profit, and return on equity through a link provided by the National Association of Investors, enhancing decision-making capabilities for potential investors.
- Independent Committee Assessment: The Editorial Advisory and Securities Review Committee of BetterInvesting, composed of several CFA members, provides authoritative support for Equifax's investment value, potentially boosting market confidence in the stock.
- Educational Investment Platform: Since 1951, BetterInvesting has focused on investment education, helping over 5 million people improve their financial futures, and Equifax's recommendation will further its educational mission, promoting investor knowledge enhancement.
See More
Neurocrine Shares Drop 8% After Mixed Earnings Despite Strong Ingrezza Sales
- Mixed Earnings Report: Neurocrine's earnings report revealed mixed results, with shares dropping 8% as overall performance fell short of market expectations, indicating investor concerns about short-term results.
- Strong Ingrezza Sales: The strong sales performance of Ingrezza highlights the product's competitiveness in the market, and while the overall earnings report was disappointing, this positive aspect may support future growth for the company.
- 2026 Outlook Meets Expectations: The company's outlook for 2026 aligns with market expectations, suggesting that despite short-term pressures, this stable forecast could bolster investor confidence and encourage long-term investment.
- Analysts See Long-Term Upside: Despite the short-term stock pressure, analysts remain optimistic about Neurocrine's long-term growth potential, believing the company is poised for improved performance in the future.
See More
Neurocrine Reports Q4 Earnings Miss Amid Strong Sales Growth
- Earnings Report: Neurocrine Biosciences reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus estimate of $1.89, indicating pressure on profitability.
- Sales Growth: The company achieved fourth-quarter sales of $805.5 million, surpassing the market expectation of $792.47 million, reflecting strong market demand.
- Product Sales Performance: Ingrezza's fourth-quarter net product sales reached $657.5 million, a 7% year-over-year increase, while Crenessity's sales were $135.3 million, driven by robust patient demand and over 80% reimbursement coverage.
- Future Outlook: The company expects fiscal 2026 Ingrezza product sales between $2.70 billion and $2.80 billion; despite concerns over a lack of near-term clinical catalysts, analysts remain optimistic about long-term growth potential.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Market Reaction Expectations: The adjustments in analyst ratings may trigger short-term market volatility, particularly when investor sentiment is sensitive to certain stocks, potentially leading to rapid price increases or decreases.
- Impact on Investor Decisions: As analysts revise their views on stocks, investors may reassess their investment strategies when considering buying or holding these stocks, thereby affecting overall market liquidity.
See More
Neurocrine Biosciences Q4 2025 Earnings Call Highlights
- Significant Growth: In 2025, Neurocrine Biosciences reported total product sales exceeding $2.8 billion, representing a 22% year-over-year increase, with INGREZZA generating over $2.5 billion in revenue, up 9%, indicating strong market demand and effective sales strategies.
- Strong CRENESSITY Launch: CRENESSITY achieved over $300 million in net sales in its first year on the market, covering over 10% of the classic adrenal hyperplasia patient population, demonstrating the company's success in product introduction and market acceptance.
- Optimistic Outlook: Management projects INGREZZA sales to range between $2.7 billion and $2.8 billion in 2026, anticipating approximately 10% growth, reflecting confidence in future market potential and ongoing investment strategies.
- Robust Cash Flow: By the end of 2025, the company's cash reserves increased to $2.5 billion, up $700 million from $1.8 billion at the end of 2024, showcasing strong operational performance and a healthy financial position that supports future R&D and market expansion.
See More
Equifax Named 'Stock to Study' for May 2026 by BetterInvesting
- Investor Interest: Equifax's recent report has sparked investor curiosity regarding whether its stock is fairly valued, leading BetterInvesting's Editorial Advisory Committee to designate it as a 'Stock to Study' for May 2026, aimed at providing information and education for investors.
- Transparency in Fundamentals: Investors can access Equifax's sales, earnings, pre-tax profit, and return on equity through a link provided by the National Association of Investors, enhancing transparency and aiding investors in making informed decisions.
- Independent Review Committee: The Editorial Advisory Committee of BetterInvesting comprises several CFA charterholders, whose independent evaluations provide deeper analytical insights, thereby increasing the research value of Equifax's stock.
- Educational Mission: Since its establishment in 1951, BetterInvesting has focused on investment education, empowering over 5 million individuals to improve their financial futures, emphasizing the importance of independent analysis before making investment decisions.
See More
Equifax Named 'Stock to Study' by BetterInvesting
- Investment Research Recommendation: Equifax has been named 'Stock to Study' for the May 2026 issue of BetterInvesting, indicating a rising interest among investors that may attract further research and investment interest.
- Transparency in Fundamentals: Investors can access key financial metrics such as sales, earnings, pre-tax profit, and return on equity through a link provided by the National Association of Investors, enhancing decision-making capabilities for potential investors.
- Independent Committee Assessment: The Editorial Advisory and Securities Review Committee of BetterInvesting, composed of several CFA members, provides authoritative support for Equifax's investment value, potentially boosting market confidence in the stock.
- Educational Investment Platform: Since 1951, BetterInvesting has focused on investment education, helping over 5 million people improve their financial futures, and Equifax's recommendation will further its educational mission, promoting investor knowledge enhancement.
See More
Neurocrine Shares Drop 8% After Mixed Earnings Despite Strong Ingrezza Sales
- Mixed Earnings Report: Neurocrine's earnings report revealed mixed results, with shares dropping 8% as overall performance fell short of market expectations, indicating investor concerns about short-term results.
- Strong Ingrezza Sales: The strong sales performance of Ingrezza highlights the product's competitiveness in the market, and while the overall earnings report was disappointing, this positive aspect may support future growth for the company.
- 2026 Outlook Meets Expectations: The company's outlook for 2026 aligns with market expectations, suggesting that despite short-term pressures, this stable forecast could bolster investor confidence and encourage long-term investment.
- Analysts See Long-Term Upside: Despite the short-term stock pressure, analysts remain optimistic about Neurocrine's long-term growth potential, believing the company is poised for improved performance in the future.
See More
Neurocrine Reports Q4 Earnings Miss Amid Strong Sales Growth
- Earnings Report: Neurocrine Biosciences reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus estimate of $1.89, indicating pressure on profitability.
- Sales Growth: The company achieved fourth-quarter sales of $805.5 million, surpassing the market expectation of $792.47 million, reflecting strong market demand.
- Product Sales Performance: Ingrezza's fourth-quarter net product sales reached $657.5 million, a 7% year-over-year increase, while Crenessity's sales were $135.3 million, driven by robust patient demand and over 80% reimbursement coverage.
- Future Outlook: The company expects fiscal 2026 Ingrezza product sales between $2.70 billion and $2.80 billion; despite concerns over a lack of near-term clinical catalysts, analysts remain optimistic about long-term growth potential.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Market Reaction Expectations: The adjustments in analyst ratings may trigger short-term market volatility, particularly when investor sentiment is sensitive to certain stocks, potentially leading to rapid price increases or decreases.
- Impact on Investor Decisions: As analysts revise their views on stocks, investors may reassess their investment strategies when considering buying or holding these stocks, thereby affecting overall market liquidity.
See More
Neurocrine Biosciences Q4 2025 Earnings Call Highlights
- Significant Growth: In 2025, Neurocrine Biosciences reported total product sales exceeding $2.8 billion, representing a 22% year-over-year increase, with INGREZZA generating over $2.5 billion in revenue, up 9%, indicating strong market demand and effective sales strategies.
- Strong CRENESSITY Launch: CRENESSITY achieved over $300 million in net sales in its first year on the market, covering over 10% of the classic adrenal hyperplasia patient population, demonstrating the company's success in product introduction and market acceptance.
- Optimistic Outlook: Management projects INGREZZA sales to range between $2.7 billion and $2.8 billion in 2026, anticipating approximately 10% growth, reflecting confidence in future market potential and ongoing investment strategies.
- Robust Cash Flow: By the end of 2025, the company's cash reserves increased to $2.5 billion, up $700 million from $1.8 billion at the end of 2024, showcasing strong operational performance and a healthy financial position that supports future R&D and market expansion.
See More
